To provide long term capital appreciation.
Name | % Net Assets |
---|---|
CELGENE CORP | 7.1% |
AMGEN INC | 7.1% |
ALEXION PHARMACEUTICALS INC | 6.7% |
VERTEX PHARMACEUTICAL | 5.4% |
TEVA PHARMACEUTICAL INDUSTRIES | 4.9% |
PHARMASSET INC | 4.5% |
SHIRE PLC | 4.4% |
ILLUMINA INC | 4.2% |
REGENERON PHARMACEUTICALS INC | 4.0% |
GILEAD SCIENCES INC | 3.8% |
Key | % Net Assets |
---|---|
CELGENE CORP | 7.1% |
AMGEN INC | 7.1% |
ALEXION PHARMACEUTICALS INC | 6.7% |
VERTEX PHARMACEUTICAL | 5.4% |
Other | 73.7% |
Date | 21-Nov-2024 |
---|---|
NAV | 265.70p |
Currency | GBP |
Change | 3.90p |
% | 1.49% |
YTD change | 7.90p |
YTD % | 3.06% |
Fund Inception | 31/12/2001 |
---|---|
Fund Manager | ANDY SMITH |
TER | 1.90 (31-Aug-2011) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £100 |
Savings | £50 |
Charges | |
---|---|
Initial | 5.50% |
Annual Mang't | 1.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.03 |
Sharpe ratio | -0.10 |
You are here: research